Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label randomized PhaseIII Study of the Efficacy and Safety of CH5424802(AF802) in ALK-Positive Advanced or Recurrecnt Non-Small Cell Lung Cancer with Crizotinib control

Trial Profile

Open-label randomized PhaseIII Study of the Efficacy and Safety of CH5424802(AF802) in ALK-Positive Advanced or Recurrecnt Non-Small Cell Lung Cancer with Crizotinib control

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms J-ALEX
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 04 Jun 2019 Results (data cut off: June 30 2018) evaluating overall survival of second interim data presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2019 Final progression free survival data presented presented in a Chugai Pharmaceutical media release.
    • 03 Jun 2019 According to a Chugai Pharmaceutical media release, final progression-free survival (PFS) data and the second interim analysis of overall survival (OS) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top